pone.0252233.g005.tif (4.56 MB)
Download file

Synergistic angiostatic activity of bevacizumab and temsirolimus is observed at 10-fold lower doses.

Download (4.56 MB)
figure
posted on 02.06.2021, 17:35 by Michael I. Dorrell, Heidi R. Kast-Woelbern, Ryan T. Botts, Stephen A. Bravo, Jacob R. Tremblay, Sarah Giles, Jessica F. Wada, MaryAnn Alexander, Eric Garcia, Gabriel Villegas, Caylor B. Booth, Kaitlyn J. Purington, Haylie M. Everett, Erik N. Siles, Michael Wheelock, Jordan A. Silva, Bridget M. Fortin, Connor A. Lowey, Allison L. Hale, Troy L. Kurz, Jack C. Rusing, Dawn M. Goral, Paul Thompson, Alec M. Johnson, Daniel J. Elson, Roujih Tadros, Charisa E. Gillette, Carley Coopwood, Amy L. Rausch, Jeffrey M. Snowbarger

To further demonstrate synergistic activity of combining bevacizumab (Avastin®) and temsirolimus (Torisel®) when blocking tumor-induced NV, each were combined at concentrations ten-fold below their maximum ineffective doses. Individual treatment with Avastin® or Torisel® had no effect on tumor NV, as expected, but in combination, tumor NV was completely blocked. (A) Representative images of the tumor onplants from the different treatment groups are shown with the original image on the left and the image showing the results of quantification on the right (B) Quantification of tumor NV demonstrated strong, synergistic angiostatic activity against tumor-derived NV (CI value = 2.42E-5). (C) Similar results were observed using the human glioblastoma cell line U87. Error bars represent SEM. X-axis groups indicate what was included in the collagen onplant.

History